D2 blockade has been implicated in having a central role in antipsychotic response. However, treatment refractoriness, in spite of complete D2 blockade, as well as the efficacy of clozapine (CLZ) in a portion of this patient population, indicates the involvement of other factors as well. Several lines of evidence suggest a role for D3. Furthermore, an earlier meta-analysis by Jönsson et al. (2003) (n ¼ 233) suggested a role for genetic variation in the D3 gene. Relevant to this study, Jönsson et al. found the Ser allele of the D3 serine-to-glycine substitution at amino acid position 9 (Ser9Gly) polymorphism to be associated with worse CLZ response compared with the Gly allele. In this study, we attempt to validate these findings by performing a meta-analysis in a much larger sample (n ¼ 758). Eight other variants were also tested in our own sample to explore the possible effect of other regions of the gene. We report a negative but consistent trend across individual studies in our meta-analysis for the DRD3 Ser allele and poor CLZ response. A possible minor role for this single-nucleotide polymorphism cannot be disregarded, as our sample size may have been insufficient. Other DRD3 variants and haplotypes of possible interest were also identified for replication in future studies.
Introduction
Treatment response in schizophrenia (SCZ) is heterogeneous. 1 A recent multicenter study found that more than 70% of patients with chronic SCZ discontinued their antipsychotic drug (APD) treatment because of poor effectiveness or tolerability. 2 Evidence from twin case studies has indicated that there may be a genetic basis for this interpatient variability. 3, 4 As the dopamine (DA) D2 receptor (D2) has been implicated in having a central role in the action of APDs, 5 several studies in the past have examined the possible association between polymorphisms in the D2 gene (DRD2) and APD response. Results from these studies, however, cannot satisfactorily explain the observed variability in patient response to APDs. 1, 6 This fact, along with the efficacy of clozapine (CLZ) in some treatment-resistant patients, in spite of a low D2 affinity, 7 suggests that other candidates may also be contributing factors to APD response. 8 The DA D3 receptor (D3) is a candidate for consideration, as most APDs have binding affinities for D3 that are similar to those for D2 (reviewed in Sokoloff et al. 9 ). Furthermore, postsynaptic D3, which is concentrated in the ventral striatum, 10 was observed to be elevated in SCZ patients who had been removed from their APDs. In contrast, D3 was downregulated in those patients who had remained medicated. 11, 12 This finding is especially interesting in the light of the proposed role of the ventral striatum in acting as a gate for modulating efferents from a number of other regions in the brain that are disturbed in SCZ. [13] [14] [15] In addition, this area is under the control of the mesolimbic DA system. Therefore, the elevation of D3 levels in the ventral striatum observed by Gurevich et al. 11 may reflect a hyperdopaminergic state of the mesolimbic DA system that is well documented in SCZ. 5, 16 This might result in an altered neural processing in the striato-pallidal-thalamo-cortical limbic loop 17, 18 and ultimately contribute to some of the symptoms seen in SCZ. The observed downregulation of D3 by APDs 11, 12 may provide a means of resolving the imbalance in this loop. 19 Although findings from preclinical animal models of APD efficacy with selective D3 antagonists have not been entirely consistent, [20] [21] [22] there is still plenty of evidence to suggest a possible role for D3 in APD response. D3 antagonists, highly selective over D2, were shown to be effective in behavioural models of positive symptoms of SCZ. [23] [24] [25] [26] Other studies have shown a beneficial effect of D3 antagonism in models of negative symptoms, 22, 27, 28 cognitive deficits 29, 30 and extrapyramidal symptoms. 21, 22, 31, 32 More relevant to this study, several lines of evidence suggest that D3 blockade may be of particular importance for the efficacy of CLZ. These include studies that have observed the reversal of phencyclidine-and neonatal ventral hippocampal lesioninduced prepulse inhibition (behavioural models of CLZ response) by selective D3 antagonism, 26, 27 and similarities between selective D3 antagonists and CLZ in their effects on patterns of immediate early gene response [33] [34] [35] [36] and depolarization inactivation of DA neurons. [37] [38] [39] Genetic association studies on the D3 gene (DRD3) have focused on a single-nucleotide polymorphism (SNP) that causes a serine-to-glycine substitution at amino acid position 9 (Ser9Gly) in the extracellular N-terminal domain of D3. Functional studies have found a significant increase in binding affinity for DA and D3 selective antagonists in cell lines transfected with the Gly allele compared with those transfected with the Ser allele. 40, 41 The Gly allele has also been observed to affect more robust DA responses in D3-mediated signal transduction pathways. These include mitogen-associated protein kinase, prostaglandin E 2 (PGE 2 ) and forskolin-stimulated cyclic adenosine monophosphate (cAMP) signalling pathways. 40, 42 One study, however, observed the opposite effect on forskolin-stimulated cAMP formation. 42 Results from the association studies between DRD3 Ser9Gly and SCZ have been inconclusive. Although initial metaanalyses have provided some evidence for a marginal association between the Ser allele, Ser-containing genotypes and Ser9Gly homozygosity with SCZ, [43] [44] [45] these findings have not been supported by larger, more recent meta-analyses. [46] [47] [48] These observations, however, do not preclude a variation in DRD3 to be irrelevant for APD response. In fact, to date, association studies between DRD3 Ser9Gly and APD response have generated promising findings. In an earlier metaanalysis performed by Jönsson et al., 44 responders to traditional APDs were observed to have higher Ser allele, Ser/Ser and homozygous genotype frequencies compared with nonresponders, whereas the reverse was true for CLZ treatment studies. With a focus on just CLZ treatment studies, we attempt to validate the findings of Jönsson et al. 44 in a substantially larger sample (Part B) by performing comprehensive meta-analyses containing all studies published to date. In this study, we were able to increase the total sample size from 233 in the Jönsson et al. study 44 to 758 To explore the possible effect of genetic variation in other DRD3 regions on CLZ response, a separate component of this study includes the association analyses of eight other SNPs in and around the DRD3 region in our own sample (Part A). Haplotype analyses were also performed.
Materials and methods
PART A: Association analyses in our sample Clinical samples. (i) Categorical response measure sample. Our sample consisted of 232 unrelated patients obtained from three research clinics: Case Western Reserve University in Cleveland, Ohio (HY Meltzer, n ¼ 105); Hillside Hospital in Glen Oaks, New York (JA Lieberman, n ¼ 92); and University of California at Irvine (SG Potkin, n ¼ 35). These subjects had Diagnostic and Statistical Manual of Mental Disorders (DSM)-III-R or DSM-IV diagnoses of SCZ 49 and almost all of whom met the criteria for treatment refractoriness or intolerance to typical APD therapy. 50 Patients were treated with CLZ and evaluated prospectively for a minimum of 6 months after a 2-to 4-week washout period, during which they did not receive any medication unless clinically necessary. CLZ blood levels were monitored throughout the course of treatment to ascertain compliance. Treatment response was evaluated using the 18-item Brief Psychiatric Rating Scale (BPRS) at the time of enrolment into the study (baseline) and after 6 months of CLZ treatment. These data were dichotomized into the categorical responder/nonresponder measure used in this study, on the basis of criteria described by Kane et al.: 50 patients with X20% reduction in the overall BPRS score from baseline were categorized as responders. This sample consisted of 183 Caucasians and 49 African Americans. A detailed description of the demographic characteristics of each clinical and ethnic group in this sample can be found in Table 1 . Differences in response rates between clinical sites were not observed (P ¼ 0.805). Therefore, data from the three clinical sites were analysed together (ii) Continuous response measure sample. Quantitative treatment response measures were available for a subsample (n ¼ 132) of the patient population described in Part A(i). These data include the overall 18-item BPRS score, a 4-item positive symptom subscale (BPOS) score (includes conceptual disorganization, suspiciousness, hallucinations and unusual thought content) and a 3-item negative symptom subscale (BNEG) score (includes emotional withdrawal, motor retardation and blunted affect) assessed at baseline and after 6 months of CLZ treatment. For the individual SNP analyses, the score change at the 6-month assessment from baseline was used as the response measure. For haplotype analyses, a percent (%) change score measure was used: % change score ¼ (6-month score-baseline score)/(baseline score). This measure was used because it is the only way to account for baseline effects in a haplotype analysis. Our subsample consisted of 97 Caucasians and 35 African Americans. A detailed description of the demographic characteristics of each clinical and ethnic group in this subsample can be found in Table 1 . Differences between clinical sites in 6-month change scores (BPRS (P ¼ 0.316); BPOS (P ¼ 0.316); BNEG (P ¼ 0.332)) and 6-month percentage change scores (BPRS (P ¼ 0.915); BPOS (P ¼ 0.729); BNEG (P ¼ 0.658)) were not observed. Therefore, data from the three clinical sites were analysed together.
Gene polymorphism analyses. Blood samples were collected from clinical sites and sent to the Centre for Addiction and Mental Health (CAMH), College Street site (Toronto, Ontario, Canada). Genomic DNA was extracted from wholeblood samples using the high-salt method described by Lahiri and Nurnberger. 51 Nine DRD3 SNPs were genotyped. From the 5 0 -to 3 0 -end of the DRD3 region, these SNPs were (1) rs905568 C/G (C ¼ Allele 1, G ¼ Allele 2) (outside of DRD3 5 0 -untranslated region (UTR), in the downstream region of the zinc-finger protein 80 gene, relative SNP position
, relative SNP position þ 32638); and (9) rs2087017 C/T (C ¼ Allele 1, T ¼ Allele 2) (in the 3 0 -UTR, relative SNP position þ 48826). The relative SNP locations are shown in Figure 1 . These SNPs were tag SNPs, chosen to minimize redundant information (high linkage disequilibrium (LD)) and maximize coverage across the DRD3 region. On the basis of data from the International HapMap Project (IHMP), 52 we would have only needed to include three additional tag SNPs to have full coverage of DRD3 in the IHMP Caucasian sample (Utah residents with ancestry from northern and western parts of Europe) at a pairwise SNP r 2 threshold of 0.80. In the African sample (Yoruban in Ibadan, Nigeria), 23 additional tag SNPs would have been required to fulfil this 
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À9.09 ± 12.32 (95) À0.13 ± 53 (ii) LD analyses. These were performed using Haploview (version 4.1). 54 LD blocks were defined on the basis of solid spine of LD criteria: D 0 40.8. (iii) Haplotype analyses. These were performed in both Caucasian and African-American samples using UNPHASED software (Cambridge, UK) for genetic association analysis (version 2.402). 55 The COCAPHASE programme (Cambridge, UK) within UNPHASED was used to assess the categorical responder/non-responder data, whereas QTPHASE within UNPHASED was used to examine the quantitative percentage change score data (BPRS, BPOS and BNEG). Global haplotype tests compared responder/non-responder proportions and mean percentage change scores across all haplotypes within a specific haplotype block. Individual haplotype tests compared the values of a specific haplotype against the pooled values of all other haplotypes with the block. Odds ratios (ORs) for significant findings from categorical data were generated using calculator for confidence intervals of OR in an unmatched case-control Study. 56 Part B: Meta-analyses of DRD3 Ser9Gly/CLZ response studies Clinical samples for meta-analyses. A computer search on the United States National Library of Medicine and National Institutes of Health online search engine database, PubMed, was performed in order to identify all papers published up to 15 October 2009 on association studies related to the DRD3 Ser9Gly polymorphism and CLZ response. Six studies were identified: Shaikh et al., 57 Gaitonde et al., 58 Malhotra et al., 59 Scharfetter et al., 60 Arranz et al. 61 and Barlas et al. 62 However, Ser9Gly genotype data for Gaitonde et al. 58 and Arranz et al. 61 were not available from their respective publications. These data were obtained directly from the authors. In addition to the 49 subjects previously reported on in Gaitonde et al., 58 we were provided with eight more subjects who were added to the sample after publication. Similarly, Arranz et al. 61 provided data for 84 more subjects who were added to the sample of 200 previously reported on. Table 2 provides a description of these six samples. It should be noted, however, that Arranz et al. 61 had incorporated the data of Shaikh et al. 57 as a part of their study sample. Therefore, the study by Shaikh et al. 57 was excluded from our meta-analyses. Including the two samples from the association analyses in Part A of this study, our meta-analyses consisted of seven samples in total, with a sample size of 758.
Statistical analysis. Meta-analyses of ORs on the effects of Ser allele vs Gly allele, Ser/Ser genotype vs Gly-containing genotypes (Ser/Gly, Gly/Gly) and homozygote genotypes (Ser/Ser, Gly/Gly) vs the heterozygote genotype (Ser/Gly) were performed using the Stata statistical software package. 63 OR and standard errors were calculated for individual studies using the 'metan' command, with the pooled OR and standard error calculated under the random effects model. Ethnicity as a possible source of heterogeneity among studies was assessed by meta-regression analysis using the 'metareg' command. We tested for publication bias using the 'metabias' command.
Results
PART A: Association analyses in our sample Individual SNP analyses. Genotype distributions for six of the nine DRD3 SNPs examined in this study were found to be significantly different between Caucasians and African 5' 3' Figure 1 Human dopamine D3 receptor gene structure and marker sites studied.
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Americans (rs2399504, rs7611535 and rs1394016 were not significantly different) (data not presented). In the light of these differences, we decided to analyse the two patient populations separately. No significant deviation from Hardy-Weinberg equilibrium was observed for any of the nine SNPs in either Caucasian or African-American samples. The quantitative 6-month change response measures (BPRS, BPOS and BNEG) were normally distributed and found to be significantly correlated with baseline scores. Baseline scores therefore were included as a covariate in the analysis of quantitative response measures. Possible confounding factors of age and gender did not have a significant influence on any of these measures in either population and therefore were not included in the analysis. No significant differences between genotypes or alleles of any of the nine SNPs were observed for response to CLZ, as measured by the dichotomous responder/non-responder variable, in either Caucasian or African-American samples (see Tables 3 and 4) .
However, there were a few findings of possible interest in comparison with quantitative response measures (see Tables  2 and 3 ). In the Caucasian sample, the A allele (allele 1) of rs2134655 was associated with better response on the BPOS rating scale (P ¼ 0.007), with perhaps a dose-dependent effect. In African Americans, heterozygotes of rs2134655 also responded better on BPOS than did GG homozygotes (no AA homozygotes were observed); however, this comparison did not reach statistical significance (P ¼ 0.089). A dosedependent relationship between the T allele of rs1394016 and better response on the BNEG scale (P ¼ 0.018), as well as a trend toward significance for the GG genotype of rs2399504 and overall BPRS response (P ¼ 0.058), was also observed in African Americans.
No association was observed for the Ser9Gly variant with any of the comparisons performed in either patient population.
LD analyses. Pairwise LD analyses between the nine SNPs in both Caucasian and African-American samples are presented in Figure 2 . As expected, a higher degree of LD was observed in the Caucasian sample than in the African-American sample. This was also observed in the Caucasian and African population data from the IHMP. 52 The Caucasian sample data from the IHMP, however, indicated a higher degree of LD compared with data from the Caucasian sample in this study. This may be because of a higher degree of homogeneity within the population sampled in the IHMP than in our sample. The degrees of LD within our AfricanAmerican sample and the IHMP African sample, however, were comparable.
Using a D 0 40.8 criteria for pairwise LD, we observed two 3-SNP LD blocks in our Caucasian sample: SNP blocks 2-3-4 and 6-7-8. SNPs 8 and 9 also formed a two-SNP haplotype block. In our African-American sample, there was also evidence for LD between SNPs 2, 3 and 4 and between SNPs 8 and 9. In addition, there were other two-SNP LD blocks observed in the African-American sample: SNP blocks 1 and 2 and 6 and 7.
Haplotype analyses. Two-marker and three-marker sliding window haplotype analyses across DRD3 were performed. These window sizes were chosen to appropriately examine haplotypes within the specific LD blocks identified by Abbreviations: BNEG, BPRS negative; BPOS, BPRS positive; BPRS, Brief Psychiatric Rating Scale; CI, confidence interval; Ser9Gly, serine-to-glycine substitution at amino acid position 9; SNP, single-nucleotide polymorphism.
Bolded values indicate a P-valueo0.05. Abbreviations: BNEG, BPRS negative; BPOS, BPRS positive; BPRS, Brief Psychiatric Rating Scale; CI, confidence interval; Ser9Gly, serine-to-glycine substitution at amino acid position 9; SNP, single-nucleotide polymorphism.
Bolded values indicate a P-valueo0.05.
LD analyses (two-marker and three-marker LD blocks, see Figure 2 ). Moreover, the sliding window approach was chosen so that we could systematically explore other haplotypes in areas of lower LD. In the Caucasian sample, haplotype analyses within the blocks identified from the LD analyses (SNP blocks 2-3-4, 6-7-8 and 8-9) found a rare haplotype in the SNP block 6-7-8 (haplotype 1-1-2) to be associated with response (P ¼ 0.037) (see Table 5 ). This haplotype was associated with non-responder CLZ treatment outcome status. This finding seems to be because of the effect of haplotype 1-1 in SNP window 6-7, as both haplotypes were observed to have similar degrees of association with responder/non-responder status.
Other significant results from the Caucasian sample include the association of Ser9Gly containing haplotypes: haplotype 1-2 in SNP window 6-7 with good BNEG response (P ¼ 0.045), haplotype 1-1 from SNP block 6-7 that was associated with non-responder status (P ¼ 0.035) and haplotype 1-2-1 from SNP block 5-6-7 that was associated with BNEG response (P ¼ 0.044).
In addition, haplotype 1-2 in SNP window 7-8 was associated with poor BNEG response (P ¼ 0.042). Haplotype 1-2-1 from SNP block 1-2-3 was associated with nonresponder status (P ¼ 0.010). This was most likely because of haplotype 1-2 from SNP block 1-2, as it had the same effect.
Finally, haplotype 2-2-2 from SNP window 3-4-5 was associated with poor BPRS response as measured by the percentage change score (P ¼ 0.033).
In the African-American sample, no haplotypes within the LD blocks identified from the LD analyses (SNP blocks 2-3-4, 1-2, 6-7 and 8-9) were found to be significant (see Table 6 ). Instead, haplotypes that contained either haplotype 1-2 or 2-1 from SNP window 4-5 were associated with good overall CLZ response as measured by the categorical responder/non-responder variable (P ¼ 0.017) and overall BPRS percentage change (P ¼ 0.049). These include haplotype 2-2-1 from SNP window 3-4-5 (P ¼ 0.021), and haplotypes 1-2-2 (P ¼ 0.035) and 2-1-2 (P ¼ 0.012) from SNP window 4-5-6. In addition, haplotype 1-1-1 from SNP window 3-4-5, which included the 1-1 SNP 4-5 haplotype, was associated with poor overall BPRS response (P ¼ 0.010); further, haplotype 2-2-2 from SNP window 4-5-6 was associated with good BPOS response (P ¼ 0.027).
Other significant findings in the African-American sample include haplotype 1-2 from SNP window 2-3 that was associated with better overall BPRS response (P ¼ 0.029) and haplotype 1-1 from SNP window 3-4 that was associated with worse overall BPRS response (P ¼ 0.049).
Part B: Meta-analyses of DRD3 Ser9Gly/CLZ response studies DRD3 Ser9Gly data from each of the studies included in the meta-analyses are presented in Table 2 .
We did not find significant differences in the Ser vs Gly allele, Ser/Ser vs Gly-carrier genotypes or homozygote vs heterozygote genotypes in responders compared with nonresponders.
The Ser allele (OR ¼ 0.82, 95% confidence interval (CI): 0.65-1.04; P ¼ 0.100) (Figure 3 ), Ser/Ser genotype (OR ¼ 0.75, 95% CI: 0.53-1.06; P ¼ 0.108) (Figure 4 ) and homozygote genotypes (OR ¼ 0.87, 95% CI: 0.64-1.17; P ¼ 0.345) ( Figure 5 ), however, occurred more frequently in nonresponders than in responders.
There was no evidence of heterogeneity among studies because of ethnicity or publication bias for any of the comparisons (data not shown).
Discussion
One of the objectives of this study was to replicate and extend the findings of the Jönsson et al. meta-analyses. 44 In their study, Jönsson et al. found the DRD3 Ser allele, the Ser/Ser genotype and homozygote genotypes (Ser/Ser and Gly/Gly genotypes combined) to occur significantly more frequently in non-responders to CLZ compared with the Gly allele (OR ¼ 0. Non-responder (n (estimated frequency))
Odds ratio (95% CI) Specific nucleotide coding for alleles 1 or 2 for each SNP can be found in Table 1 .
Bolded values indicate a P-valueo0.05. Specific nucleotide coding for alleles 1 or 2 for each SNP can be found in Table 1 .
association studies published at the time. 57, 59, 60 The Jönsson et al. meta-analyses did not contain data from either Arranz et al. 61 or Gaitonde et al., 58 most likely because those raw data had not been published. In the present meta-analyses, these data have been included and were obtained directly from the authors. Gaitonde et al. and Arranz et al. also provided us with additional subjects who were added to their respective samples subsequent to publication. Data from the study by Shaikh et al., 57 however, had to be excluded from the current meta-analyses, as their data had been incorporated into the Arranz et al. study already. CLZ data from three other samples were also included in the present meta-analyses: the two samples from the present study and the sample from the study by Barlas et al. Figure 4 Meta-analysis of clozapine (CLZ) response studies comparing effects of the DRD3 Ser/Ser genotype vs Gly carrier genotypes (Ser/Gly þ Gly/Gly).
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In total, we increased the sample size from 233 in the Jönsson et al. study to 758 in the present, comprehensive meta-analyses (more than three times larger).
In contrast to Jönsson et al., we did not observe an association between the DRD3 Ser allele (P ¼ 0.100), Ser/Ser (P ¼ 0.108) or homozygote genotypes (P ¼ 0.345) with poor overall CLZ response in our meta-analyses. However, an interesting feature observed by us was the consistency across the individual studies: in six of the seven studies, the Ser allele, Ser/Ser genotype and homozygote genotypes shared the same direction of effect (ORo1) towards poor response (with Gaitonde et al. 58 being the exception). Although most of the effect sizes are small, this feature indicates that we cannot rule out the possibility of a minor role of the Ser9Gly variant in CLZ response on the basis of this negative result. Moreover, we should consider that the true magnitude of genetic effects is usually less than that described in the initial reports of association, owing to the phenomenon of the 'winner's curse' (discussed in Ioannidis et al. 64 and Lohmueller et al. 65 ). Therefore, the initial positive findings observed in Jönsson et al. and the results in the present meta-analyses could be interpreted in either of the two following ways: (1) the Jönsson et al. finding reflects a false positive that will continue to lose statistical significance as more data are accumulated; or (2) there is indeed a true association between DRD3 Ser9Gly and overall CLZ response that was exaggerated in Jönsson et al., but is finding a more appropriate, smaller effect size in this larger study. If there is a real effect of DRD3 Ser9Gly on overall CLZ response, and it is in fact a small one, as would be expected for a complex phenotype, then the sample size may need to be increased significantly to convincingly identify this variant as a predictor of APD response. Newton-Cheh and Hirschhorn 66 offered a sample size range of 1000-10 000 patients that would be needed to achieve significance (Po0.05) for common variants of modest effect.
In addition to insufficient sample size, our negative result in the meta-analyses, in spite of the consistency observed across individual studies, may also be explained by an unfavourable signal-to-noise ratio. This may be the case, especially considering the heterogeneous nature of meta-analytic studies. In other words, confounding variables may have prevented the observed trend from becoming statistically significant. Possible factors that could have increased the 'noise' in our study include ethnicity, age, gender, duration of illness, co-medication, compliance, plasma levels, smoking, pharmacokinetic factors, and so on. In our meta-analyses, we were able to test but did not find ethnicity to be a confounding factor. Unfortunately, because of differences in study design and availability of raw data, we were unable to test and account for the other possible confounding variables mentioned.
Considering the possibility that the DRD3 Ser9Gly variant has an effect on CLZ response, its possible modes of action are unknown. The Gly allele, however, in addition to being associated with increased binding affinity to DA-and D3-selective antagonists, 40, 41 has also been linked to having more robust effects on various signal transduction systems. 40, 42 Signal transduction systems translate the short-term interactions between neurotransmitters and receptors into long-term adaptive changes in neural activity. This may explain why repeated short-term receptor blockade can result in progressive effectiveness over several weeks of therapy. It is therefore important to consider any effects Figure 5 Meta-analysis of clozapine (CLZ) response studies comparing effects of DRD3 homozygote genotypes (Ser/Ser þ Gly/Gly) vs the heterozygote genotype (Ser/Gly).
DRD3 polymorphisms and clozapine response that variation in D3 may have on signal transduction function in order to understand its possible contribution to CLZ response, and to APD response in general.
One signal transduction system to consider is the cAMP pathway. This system is of particular relevance, as all DA receptors are either positively or negatively linked to it. Increased cerebrospinal fluid cAMP levels have been observed in SCZ, 67 whereas normalization of these levels has been associated with AP treatment 67, 68 and response to AP treatment. 69 The effect of D3 on this system has been derived through in vitro experiments. Agonism at D3 was shown to inhibit forskolin-stimulated cAMP production, 40, 42, 70, 71 whereas selective D3 antagonism blocked this effect. 70 In addition, the effect of DA on inhibiting forskolin-stimulated cAMP production was found to be altered by DRD3 Ser9Gly variation. 40, 42 Prostaglandin signalling is another system to consider in view of the immune imbalance and inflammatory process hypothesis of SCZ (reviewed in Muller et al. 72 ). To elaborate, elevated levels of PGE 2 , a signalling molecule, were associated with SCZ and symptom severity. 73 In addition, a beneficial effect on treatment outcome of cyclooxygenase-2 (COX-2) inhibitor add-on treatment to risperidone was observed. 74 Inhibition of COX-2, an upstream regulator of PGE 2 , is expected to reduce PGE 2 levels. Further evidence for a possible role of PGE 2 in SCZ and AP response is the antiinflammatory modulatory effect of APs, including CLZ, on cytokines upstream (tumour necrosis factor-a) and downstream (interleukin-2, -6, -10) of PGE 2 (reviewed in Sugino et al. 75 and Monteleone et al.
76
). These cytokines have also been associated with SCZ (reviewed in Muller et al. 72 ). Of interest, D3 has been linked to PGE 2 signalling through experiments in vitro. It was shown that D3 mediates DA and D3 antagonist inhibition of stimulus-evoked release of PGE 2 42 and arachidonic acid. 77 Furthermore, Hellstrand et al. 42 showed that the effect of DA and D3 antagonists on inhibition of PGE 2 release only occurs in cells transfected with the Gly variant, not the Ser variant. This may be why the Gly allele, in particular, was observed more frequently, although non-significantly, in patients who responded more favourably to CLZ treatment in the meta-analyses conducted in this study.
Another pathway that D3 may affect is the mitogenactivated protein kinase (MAPK) pathway. This system is implicated in the pathophysiology of SCZ because postmortem studies have found MAPK protein and mRNA levels to be increased in SCZ brains. 78 Furthermore, various APs, both typical and atypical, have been shown to alter the MAPK pathway (reviewed in Browning et al. 79 ). Particularly relevant to this study, CLZ selectively activated the MAPK/extracellular signal-regulated kinase (a specific MAPK pathway) pathway in vitro, 79, 80 whereas inhibition of this pathway reversed the actions of CLZ in the conditioned avoidance response mouse model of psychosis, 79 providing stronger evidence that this pathway may have a role in the AP effect of CLZ. It has been shown in vitro that MAPK activation by DA is a D3-mediated response. 70, 81 Moreover, DRD3 Ser9Gly variation has previously been shown to have differential effects on this response, with the Gly allele having a more prolonged response than the Ser allele. 40 Exactly what effect DRD3 Ser9Gly variation might have on these pathways or in ligand binding to D3, however, is unclear. Although it has been suggested that this polymorphism may alter transduction properties by affecting posttranslational glycosylation, 42 Jeanneteau et al. 40 provided evidence to the contrary. This polymorphism, located in the extracellular tail of the receptor, does not lie in regions of the receptor protein that would usually be expected to be involved in signal transduction or ligand binding. However, Jeanneteau et al. 40 proposed that the Ser9Gly variant may affect these properties by changing the overall conformation of the receptor and influencing the ability of D3 to form oligomers. Indeed, there is abundant evidence that the formation of oligomers is important for the signalling functions of G-protein-coupled receptors (reviewed in Bouvier 82 ). Furthermore, it has been shown in vivo that D3 forms dimers 83 and that hetero-oligomerization of wild-type D3 with mutant receptors alters ligandbinding affinity. 84 However, as the functional effects of this SNP have been mostly obtained in vitro, it is difficult to speculate on its possible mode of action in vivo. Another question that remains is whether and how the possible functional effects that this SNP has on signal transduction pathways may translate into CLZ/AP treatment outcome effect. One possibility may be through downregulation of D3 levels in the ventral striatum as previously described. 11, 12 A further examination of these issues is warranted.
Another item to consider is why the effect of the Ser9Gly variant in Gaitonde et al. was again, although nonsignificantly, in the opposite direction to the other six studies included in the meta-analyses. Their results were unlikely to be because of population differences, as the sample consisted of Caucasian patients (as did five of the six other studies) and was recruited from the United Kingdom (as were two other studies) (see Table 2 ). The discrepancies observed in Gaitonde et al. were also unlikely to be because of the response criteria used in that study. Although the criteria used were not reported, the response rate of 53% was well within the range of most of the other studies in the meta-analyses (see Table 7 ). Alternative explanations involving these particular confounding variables are therefore unlikely, although other factors are still possible, as discussed earlier. If the Ser9Gly variant is not itself a true causal variant, then it may be in incomplete LD with a different variant of true causal effect instead. If this is the case, then it may be worthwhile to examine other SNPs that are in tight LD with Ser9Gly. These SNPs should also be analysed in combination as haplotypes, as this approach may be more revealing than considering each SNP individually. 85 Although the same haplotypes were not tested in our own samples in this study, previous association studies have found specific haplotypes, containing Ser9Gly and tightly linked SNPs from the 5 0 region, 86, 87 as well as from the 3 0 region 88 of the gene, to be associated with SCZ, in spite of the Ser9Gly variant not being significant by itself.
In this study, although the Ser9Gly SNP was negative, haplotype analyses showed some haplotypes that were associated with CLZ response in both the Caucasian and African-American samples. Positive reports on haplotypes spanning non-coding regions of the gene indicate that the Ser9Gly variant may be linked to elements that regulate transcription. These results indicate that in addition to a possible effect on signal transduction or ligand binding, one of the functional consequences of DRD3 variation may be altered levels of gene expression.
In addition to the Ser9Gly meta-analyses, we also examined nine tag SNPs (including Ser9Gly) spanning the DRD3 region from 5 0 -UTR to 3 0 -UTR in our own samples. The purpose was not to study closely linked variants to Ser9Gly, but rather to explore other regions of the gene. We found SNP 8 (rs2134655, intron 5) to be associated with positive symptoms in Caucasians, as well as to have a possible trend in African Americans. In turns out, in fact, that this SNP was observed to be in strong LD with Ser9Gly (SNP 6) in Caucasians and moderate LD in African Americans. Therefore, rs2134655 could be contributing to or even responsible for the positive findings of Ser9Gly in previous studies, although it is not clear what function rs2134655 might have. In any case, rs2134655 could be a marker for consideration in future DRD3 studies.
Another finding of interest is the association, before correction for multiple testing, of rs1394016 with negative symptoms in African Americans. Although not observed in Caucasians, it should be noted that the most promising indication of D3 receptor blockade may be the amelioration of negative symptoms (and cognitive symptoms) (reviewed in Joyce and Millan 89 ). Overall, our findings are in line with previous studies that have implicated D3 antagonism not only for general APD effect but also specifically for the mechanism of action of CLZ, and its resulting unique therapeutic profile (that is, an effect on negative symptoms (reviewed in Naheed and Green 90 ; see Introduction)). An issue relating to our exploratory analysis is correction for multiple testing. As we explored the effect of nine SNPs across DRD3, an adjusted P-value threshold for statistical significance was calculated using the SNPSpD programme (Brisbane, Queensland, Australia). 91 This programme corrects for testing of multiple markers by generating an a-threshold that takes into account the LD between the SNPs studied. The corrected significance thresholds were P-value of 0.007 in the Caucasian sample and P-value of 0.006 in the AfricanAmerican sample. When applying these thresholds to our findings, the rs2134655 result in the Caucasian sample still remains significant, whereas results in the African-American sample become negative. As the number of SNPs in our study is not large, to avoid the risk of false negatives, we chose to highlight our negative trending results. We will leave it to the discretion of others whether or not to examine these SNPs in independent samples in order to explore their potential significance.
With regard to statistical power, on the basis of the lowest minor allele frequencies (MAFs) (see Tables 1 and 2 ), our Caucasian sample (lowest MAFE20%; 167 non-responders; Table 7 DRD3 Ser9Gly data from each study included in meta-analyses Abbreviations: DRD3, D3 gene; NR, non-responders; R, responders; Ser9Gly, serine-to-glycine substitution at amino acid position 9; SNP, single-nucleotide polymorphism.
1.34 responder/non-responder ratio) had at least 80% power to detect an effect size of as high as 1.65/0.61 at a ¼ 0.05. Using the same criteria, our African-American sample (49 non-responders; 1.04 responder/non-responder ratio) has at least 80% power to detect an effect size as high as 2.8/0.36.
92
In spite of studies showing questionable efficacy of D3-preferring ligands in clinical trials, 93, 94 the possibility that D3 may still be important for modulating AP response remains. In this study, we provide evidence suggesting that a minor role for DRD3 variation in CLZ response cannot be dismissed. Additional studies on Ser9Gly need to be performed in order to increase the collective sample size in the literature so that the possible role of this variant can be more clearly defined. Furthermore, functional studies on SNPs in regulatory elements in LD with the Ser9Gly polymorphism should be examined.
